Movano

FDA Clearance And Partnerships Will Expand Wearable Healthcare Reach

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

27 Apr 25

Updated

29 Oct 25

n/a

AnalystConsensusTarget's Fair Value

n/a

-86.3%

1.7%

-86.3%

1.7%

You can edit this narrative until Oct 30 11:40 PM. Then, changes will post as Updates.

Author's Valuation

US$30097.0% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates2

Shared on 29 Oct 25

Fair value Increased 900%

Analysts have sharply raised their price target for Movano from $30.00 to $300.00. They cite substantial upgrades in projected revenue growth, improved profit margins, and a lower discount rate, all of which support a much higher fair value estimate.

Shared on 01 May 25

AnalystConsensusTarget Fair Value

US$300

97.0% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

0.00%

Tech Hardware revenue growth rate

0.26%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

9.43%

Calculation

US$14.48m

Earnings '28

43.80x

PE Ratio '28

US$634.23m

Market Cap '28

US$634.23m

Market Cap '28

1.66m

No. shares '28

US$381.00

Share Price '28

US$381.00 Share Price '28

Discounted to 2025 @ 8.29% p.a.

US$300.00

Fair Value '25